Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors.

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol (2010) 4.81

Integrins: masters and slaves of endocytic transport. Nat Rev Mol Cell Biol (2009) 3.52

Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov (2011) 3.26

Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat Rev Mol Cell Biol (2011) 3.25

Nrf2: friend or foe for chemoprevention? Carcinogenesis (2009) 2.72

Use of the mouse aortic ring assay to study angiogenesis. Nat Protoc (2011) 2.42

Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov (2010) 2.27

Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res (2009) 2.23

Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem (2010) 1.87

Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J Clin Invest (2012) 1.85

Focal adhesion kinase is required for intestinal regeneration and tumorigenesis downstream of Wnt/c-Myc signaling. Dev Cell (2010) 1.79

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer (2009) 1.78

Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome. Nature (2010) 1.70

Why integrin as a primary target for imaging and therapy. Theranostics (2011) 1.61

Endocytosis and signaling: cell logistics shape the eukaryotic cell plan. Physiol Rev (2012) 1.61

Endothelial von Willebrand factor regulates angiogenesis. Blood (2010) 1.47

Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol (2012) 1.46

Extracellular matrix, inflammation, and the angiogenic response. Cardiovasc Res (2010) 1.45

Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro Oncol (2011) 1.38

{beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am J Pathol (2009) 1.37

αV integrins in angiogenesis and cancer. Cold Spring Harb Perspect Med (2011) 1.33

Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov (2012) 1.33

Integrin trafficking at a glance. J Cell Sci (2012) 1.19

Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel. Biomaterials (2011) 1.17

Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer. Dose Response (2010) 1.16

Phage nanofibers induce vascularized osteogenesis in 3D printed bone scaffolds. Adv Mater (2014) 1.16

Alphav beta3 integrin limits the contribution of neuropilin-1 to vascular endothelial growth factor-induced angiogenesis. J Biol Chem (2009) 1.15

Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner. Proc Natl Acad Sci U S A (2011) 1.13

Integrins and bone metastasis: integrating tumor cell and stromal cell interactions. Bone (2010) 1.09

The aortic ring model of angiogenesis: a quarter century of search and discovery. J Cell Mol Med (2009) 1.07

Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies. Genes Cancer (2011) 1.06

Integrin-based therapeutics: biological basis, clinical use and new drugs. Nat Rev Drug Discov (2016) 1.06

Interplay between cell adhesion and growth factor receptors: from the plasma membrane to the endosomes. Cell Tissue Res (2009) 1.05

Imaging key biomarkers of tumor angiogenesis. Theranostics (2012) 1.03

VEGFR2 and Src kinase inhibitors suppress Andes virus-induced endothelial cell permeability. J Virol (2010) 1.02

Endothelial alpha3beta1-integrin represses pathological angiogenesis and sustains endothelial-VEGF. Am J Pathol (2010) 1.02

Essential role for endocytosis in the growth factor-stimulated activation of ERK1/2 in endothelial cells. J Biol Chem (2013) 0.94

Reproducibility study of [(18)F]FPP(RGD)2 uptake in murine models of human tumor xenografts. Eur J Nucl Med Mol Imaging (2010) 0.93

Integrin α3β1 as a breast cancer target. Expert Opin Ther Targets (2011) 0.93

FAK-heterozygous mice display enhanced tumour angiogenesis. Nat Commun (2013) 0.92

Integrin inhibitors as a therapeutic agent for ovarian cancer. J Oncol (2011) 0.90

Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrin. Proc Natl Acad Sci U S A (2011) 0.90

Endosome-to-Plasma Membrane Recycling of VEGFR2 Receptor Tyrosine Kinase Regulates Endothelial Function and Blood Vessel Formation. Cells (2014) 0.90

Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors. Eur J Cancer (2010) 0.89

FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism. Clin Cancer Res (2011) 0.88

A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. Neuro Oncol (2015) 0.88

Exploring new near-infrared fluorescent disulfide-based cyclic RGD peptide analogs for potential integrin-targeted optical imaging. Bioorg Med Chem Lett (2011) 0.88

Endothelial-Rac1 is not required for tumor angiogenesis unless alphavbeta3-integrin is absent. PLoS One (2010) 0.88

Gene expression analysis in human breast cancer associated blood vessels. PLoS One (2012) 0.87

Structural basis for pure antagonism of integrin αVβ3 by a high-affinity form of fibronectin. Nat Struct Mol Biol (2014) 0.87

An in vivo neovascularization assay for screening regulators of angiogenesis and assessing their effects on pre-existing vessels. Angiogenesis (2012) 0.87

Adhesion maturation of neutrophils on nanoscopically presented platelet glycoprotein Ibα. ACS Nano (2013) 0.87

RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis. Cancers (Basel) (2012) 0.87

Synthesis and evaluation of new iRGD peptide analogs for tumor optical imaging. Bioorg Med Chem Lett (2010) 0.87

Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer. Cancer Biol Ther (2011) 0.86

Expression of integrin genes and proteins in progression and dissemination of colorectal adenocarcinoma. BMC Clin Pathol (2013) 0.86

An inhibitor of a cell adhesion receptor stimulates cell migration. Angew Chem Int Ed Engl (2010) 0.86

Decreased cell adhesion promotes angiogenesis in a Pyk2-dependent manner. Exp Cell Res (2011) 0.86

Single and combined effects of alphavbeta3- and alpha5beta1-integrins on capillary tube formation in a human fibrinous matrix. Angiogenesis (2009) 0.85

The role of integrins in the trabecular meshwork. J Ocul Pharmacol Ther (2013) 0.85

A small-molecule RGD-integrin antagonist inhibits cell adhesion, cell migration and induces anoikis in glioblastoma cells. Int J Oncol (2012) 0.85

Cellular characterization of ultrasound-stimulated microbubble radiation enhancement in a prostate cancer xenograft model. Dis Model Mech (2014) 0.84

Focal adhesion complex proteins in epidermis and squamous cell carcinoma. Cell Cycle (2013) 0.84

Anticancer and antiangiogenic activity of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer therapy. J Control Release (2011) 0.84

Applications of snake venom components to modulate integrin activities in cell-matrix interactions. Int J Biochem Cell Biol (2013) 0.84

Vinculin activators target integrins from within the cell to increase melanoma sensitivity to chemotherapy. Mol Cancer Res (2011) 0.83

RAM, an RGDS analog, exerts potent anti-melanoma effects in vitro and in vivo. PLoS One (2011) 0.83

Integrin α(v)β₃-targeted radiotracer (99m)Tc-3P-RGD₂ useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin α(v)β₃ RGD₂ therapy. Theranostics (2013) 0.83

Role of the AP-1 transcription factor FOSL1 in endothelial cells adhesion and migration. Cell Adh Migr (2013) 0.82

Role of microRNA-150 and glycoprotein nonmetastatic melanoma protein B in angiogenesis during hyperoxia-induced neonatal lung injury. Am J Respir Cell Mol Biol (2015) 0.81

Tumor angiogenesis in the absence of fibronectin or its cognate integrin receptors. PLoS One (2015) 0.81

Will integrin inhibitors have proangiogenic effects in the clinic? Nat Med (2009) 0.80

Modulation of the tumor vasculature and oxygenation to improve therapy. Pharmacol Ther (2015) 0.80

Effects of a novel cyclic RGD peptidomimetic on cell proliferation, migration and angiogenic activity in human endothelial cells. Vasc Cell (2014) 0.80

The role of integrins in TGFβ activation in the tumour stroma. Cell Tissue Res (2016) 0.80

Synchronized cell attachment triggered by photo-activatable adhesive ligands allows QCM-based detection of early integrin binding. Sci Rep (2015) 0.79

Near-infrared fluorescent divalent RGD ligand for integrin αvβ₃-targeted optical imaging. Bioorg Med Chem Lett (2012) 0.79

Integrin-mediated cell-matrix interaction in physiological and pathological blood vessel formation. J Oncol (2011) 0.79

Anti-angiogenic alternatives to VEGF blockade. Clin Exp Metastasis (2015) 0.79

Orally active αvβ3 integrin inhibitor MK-0429 reduces melanoma metastasis. Oncol Rep (2015) 0.79

FKBPL is a critical antiangiogenic regulator of developmental and pathological angiogenesis. Arterioscler Thromb Vasc Biol (2015) 0.78

Future paradigms for precision oncology. Oncotarget (2016) 0.78

Laminin α5-derived peptides modulate the properties of metastatic breast tumour cells. Clin Exp Metastasis (2011) 0.78

3D bioprinting: improving in vitro models of metastasis with heterogeneous tumor microenvironments. Dis Model Mech (2017) 0.78

Constitutive Endocytosis of VEGFR2 Protects the Receptor against Shedding. J Biol Chem (2016) 0.77

Hormesis: Decoding Two Sides of the Same Coin. Pharmaceuticals (Basel) (2015) 0.77

Ultrasmall integrin-targeted silica nanoparticles modulate signaling events and cellular processes in a concentration-dependent manner. Small (2014) 0.77

Antagonizing Integrin β3 Increases Immunosuppression in Cancer. Cancer Res (2016) 0.77

Synthesis and evaluation of the aldolase antibody-derived chemical-antibodies targeting α5β1 integrin. Mol Pharm (2012) 0.76

Matrix control of pancreatic cancer: New insights into fibronectin signaling. Cancer Lett (2015) 0.76

The role of integrins in glaucoma. Exp Eye Res (2016) 0.76

Cilengitide affects tumor compartment, vascularization and microenvironment in experimental bone metastases as shown by longitudinal ¹⁸F-FDG PET and gene expression analysis. J Cancer Res Clin Oncol (2012) 0.76

Suppression of β3-integrin in mice triggers a neuropilin-1-dependent change in focal adhesion remodelling that can be targeted to block pathological angiogenesis. Dis Model Mech (2015) 0.76

Can Integrin Agonists Have Cards to Play against Cancer? A Literature Survey of Small Molecules Integrin Activators. Cancers (Basel) (2017) 0.76

Endogenous migration modulators as parent compounds for the development of novel cardiovascular and anti-inflammatory drugs. Br J Pharmacol (2012) 0.75

Identification of an Endogenously Generated Cryptic Collagen Epitope (XL313) That May Selectively Regulate Angiogenesis by an Integrin Yes-associated Protein (YAP) Mechano-transduction Pathway. J Biol Chem (2015) 0.75

Targeting Integrin-Dependent Adhesion and Signaling with 3-Arylquinoline and 3-Aryl-2-Quinolone Derivatives: A new Class of Integrin Antagonists. PLoS One (2015) 0.75

Endogenous ribosomal protein L29 (RPL29): a newly identified regulator of angiogenesis in mice. Dis Model Mech (2012) 0.75

Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism. Acta Neuropathol (2016) 0.75

Blocking integrin inactivation as an anti-angiogenic therapy. EMBO J (2015) 0.75

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19

Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science (1994) 12.83

VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol (2006) 12.09

Vascular endothelial growth factor (VEGF) and its receptors. FASEB J (1999) 10.09

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov (2004) 9.96

Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 9.51

VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer (2008) 7.86

Clinical translation of angiogenesis inhibitors. Nat Rev Cancer (2002) 6.58

Cancer biology and hormesis: human tumor cell lines commonly display hormetic (biphasic) dose responses. Crit Rev Toxicol (2005) 4.93

Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med (2002) 4.87

Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res (1999) 4.20

Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J Cell Biol (2006) 3.95

Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest (1995) 3.69

Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol (2007) 3.29

PDGF-regulated rab4-dependent recycling of alphavbeta3 integrin from early endosomes is necessary for cell adhesion and spreading. Curr Biol (2001) 3.13

Regulators of endocytosis maintain localized receptor tyrosine kinase signaling in guided migration. Dev Cell (2005) 3.10

Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res (2001) 3.01

N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem (1999) 2.76

Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments. J Cell Biol (2008) 2.61

In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res (2004) 2.46

Integrins and cancer. Curr Opin Cell Biol (1996) 2.44

A reevaluation of integrins as regulators of angiogenesis. Nat Med (2002) 2.36

Endocytic transport of integrins during cell migration and invasion. Trends Cell Biol (2008) 2.20

The fibronectin-binding integrins alpha5beta1 and alphavbeta3 differentially modulate RhoA-GTP loading, organization of cell matrix adhesions, and fibronectin fibrillogenesis. J Cell Biol (2002) 2.14

Integrin signaling is critical for pathological angiogenesis. J Exp Med (2006) 1.91

Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery (2001) 1.90

Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice. Cancer Res (2004) 1.88

VEGF regulates the mobilization of VEGFR2/KDR from an intracellular endothelial storage compartment. Blood (2006) 1.87

Intrinsic tyrosine kinase activity is required for vascular endothelial growth factor receptor 2 ubiquitination, sorting and degradation in endothelial cells. Traffic (2006) 1.78

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer (2003) 1.75

Moving membrane up to the front of migrating cells. Cell (1996) 1.70

Rab11-family interacting protein 2 and myosin Vb are required for CXCR2 recycling and receptor-mediated chemotaxis. Mol Biol Cell (2004) 1.70

Integrins: molecular targets in cancer therapy. Curr Oncol Rep (2006) 1.63

alphavbeta3 integrin and angiogenesis: a moody integrin in a changing environment. Curr Opin Cell Biol (2008) 1.57

Vascular endothelial growth factor-dependent down-regulation of Flk-1/KDR involves Cbl-mediated ubiquitination. Consequences on nitric oxide production from endothelial cells. J Biol Chem (2003) 1.51

alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis (2003) 1.48

Integrins in angiogenesis: multitalented molecules in a balancing act. Cell Tissue Res (2003) 1.42

Blockade of alpha v beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells. Blood (2006) 1.40

alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer (2002) 1.36

Epidermal growth factor receptor distribution during chemotactic responses. Mol Biol Cell (2000) 1.34

A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer (2006) 1.31

Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents. J Neurooncol (2000) 1.29

Alpha v integrin inhibitors and cancer therapy. Curr Opin Investig Drugs (2003) 1.28

Superactivation of integrin alphavbeta3 by low antagonist concentrations. J Cell Sci (2001) 1.28

Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol (2007) 1.19

Integrin inhibitors reaching the clinic. J Clin Oncol (2007) 1.12

In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. Int J Cancer (2000) 1.11

Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo. Br J Cancer (2002) 1.03

Manganese-induced integrin affinity maturation promotes recruitment of alpha V beta 3 integrin to focal adhesions in endothelial cells: evidence for a role of phosphatidylinositol 3-kinase and Src. Thromb Haemost (2004) 0.98

Substituted benzocyloheptenes as potent and selective alpha(v) integrin antagonists. Bioorg Med Chem Lett (2002) 0.86

Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med (2002) 4.87

Mutant p53 drives invasion by promoting integrin recycling. Cell (2009) 4.75

Rab25 associates with alpha5beta1 integrin to promote invasive migration in 3D microenvironments. Dev Cell (2007) 3.84

Integrins: masters and slaves of endocytic transport. Nat Rev Mol Cell Biol (2009) 3.52

Integrin trafficking and the control of cell migration. Traffic (2006) 2.89

Unilateral multicystic dysplastic kidney: does initial size matter? Pediatr Nephrol (2012) 2.79

Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments. J Cell Biol (2008) 2.61

p53 and its mutants in tumor cell migration and invasion. J Cell Biol (2011) 2.49

Endocytic recycling pathways: emerging regulators of cell migration. Curr Opin Cell Biol (2006) 2.48

Use of the mouse aortic ring assay to study angiogenesis. Nat Protoc (2011) 2.42

alpha v beta3 and alpha5beta1 integrin recycling pathways dictate downstream Rho kinase signaling to regulate persistent cell migration. J Cell Biol (2007) 2.31

Efficient, inducible Cre-recombinase activation in vascular endothelium. Genesis (2008) 2.21

P-Rex1 is required for efficient melanoblast migration and melanoma metastasis. Nat Commun (2011) 2.18

Neuropilin-1/GIPC1 signaling regulates alpha5beta1 integrin traffic and function in endothelial cells. PLoS Biol (2009) 2.16

RhoB and actin polymerization coordinate Src activation with endosome-mediated delivery to the membrane. Dev Cell (2004) 2.13

A direct role for Met endocytosis in tumorigenesis. Nat Cell Biol (2011) 2.11

Mechanisms of integrin activation and trafficking. Curr Opin Cell Biol (2011) 2.00

Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res (2008) 1.94

Protein kinase B/Akt acts via glycogen synthase kinase 3 to regulate recycling of alpha v beta 3 and alpha 5 beta 1 integrins. Mol Cell Biol (2004) 1.93

Survey of acute renal failure in patients with cystic fibrosis in the UK. Thorax (2007) 1.93

Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice. Cancer Res (2004) 1.88

VEGF regulates the mobilization of VEGFR2/KDR from an intracellular endothelial storage compartment. Blood (2006) 1.87

Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression. Dev Cell (2011) 1.87

Distinct roles of talin and kindlin in regulating integrin α5β1 function and trafficking. Curr Biol (2012) 1.86

A crucial role for Fgfr2-IIIb signalling in epidermal development and hair follicle patterning. Development (2003) 1.79

Integrins: the keys to unlocking angiogenesis. Arterioscler Thromb Vasc Biol (2008) 1.75

Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol (2006) 1.74

Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome. Nature (2010) 1.70

PKD1/PKCmu promotes alphavbeta3 integrin recycling and delivery to nascent focal adhesions. EMBO J (2004) 1.69

Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression. Gastroenterology (2011) 1.63

Patients with recessive dystrophic epidermolysis bullosa develop squamous-cell carcinoma regardless of type VII collagen expression. J Invest Dermatol (2007) 1.57

Stromal features are predictive of disease mortality in oral cancer patients. J Pathol (2011) 1.54

Continuous venovenous hemofiltration with or without extracorporeal membrane oxygenation in children. Pediatr Crit Care Med (2007) 1.54

Cell adhesion through alphaV-containing integrins is required for efficient HIV-1 infection in macrophages. Blood (2008) 1.53

Effectiveness of a cardiology review course for internal medicine residents using simulation technology and deliberate practice. Teach Learn Med (2002) 1.47

The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development. EMBO J (2007) 1.45

N-WASP coordinates the delivery and F-actin-mediated capture of MT1-MMP at invasive pseudopods. J Cell Biol (2012) 1.45

Basic fibroblast growth factor activates the MAPK and NFkappaB pathways that converge on Elk-1 to control production of matrix metalloproteinase-13 by human adult articular chondrocytes. J Biol Chem (2007) 1.44

Beta3-integrin regulates vascular endothelial growth factor-A-dependent permeability. Arterioscler Thromb Vasc Biol (2004) 1.41

Blockade of alpha v beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells. Blood (2006) 1.40

Comparison of two micronutrient supplements in children with chronic renal failure. J Ren Nutr (2002) 1.39

A direct functional link between the multi-PDZ domain protein GRIP1 and the Fraser syndrome protein Fras1. Nat Genet (2004) 1.39

Endothelial FAK is required for tumour angiogenesis. EMBO Mol Med (2010) 1.38

Site-directed perturbation of protein kinase C- integrin interaction blocks carcinoma cell chemotaxis. Mol Cell Biol (2002) 1.35

Renal replacement therapy for acute renal failure in children: European guidelines. Pediatr Nephrol (2003) 1.35

HS1-associated protein X-1 regulates carcinoma cell migration and invasion via clathrin-mediated endocytosis of integrin alphavbeta6. Cancer Res (2007) 1.33

Paxillin associates with poly(A)-binding protein 1 at the dense endoplasmic reticulum and the leading edge of migrating cells. J Biol Chem (2001) 1.31

Integrin trafficking and its role in cancer metastasis. Cancer Metastasis Rev (2007) 1.29

FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res (2011) 1.29

B-Raf acts via the ROCKII/LIMK/cofilin pathway to maintain actin stress fibers in fibroblasts. Mol Cell Biol (2004) 1.28

S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool. J Pharmacol Exp Ther (2008) 1.28

Epigenetic inactivation of protein kinase D1 in gastric cancer and its role in gastric cancer cell migration and invasion. Carcinogenesis (2008) 1.24

Alpha v beta3 integrin spatially regulates VASP and RIAM to control adhesion dynamics and migration. J Cell Biol (2010) 1.24

Antibody against junctional adhesion molecule-C inhibits angiogenesis and tumor growth. Cancer Res (2005) 1.23

alpha3beta1 integrin-controlled Smad7 regulates reepithelialization during wound healing in mice. J Clin Invest (2008) 1.22

Organotypic culture model of pancreatic cancer demonstrates that stromal cells modulate E-cadherin, beta-catenin, and Ezrin expression in tumor cells. Am J Pathol (2009) 1.22

Diacylglycerol kinase α controls RCP-dependent integrin trafficking to promote invasive migration. J Cell Biol (2012) 1.21

Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer. Cancer Res (2012) 1.20

Integrin trafficking at a glance. J Cell Sci (2012) 1.19

Renal biopsies in children: current practice and audit of outcomes. Nephrol Dial Transplant (2009) 1.19

Structure-function analysis of Arg-Gly-Asp helix motifs in alpha v beta 6 integrin ligands. J Biol Chem (2007) 1.18

Lack of plakophilin 1 increases keratinocyte migration and reduces desmosome stability. J Cell Sci (2003) 1.16

Bone marrow cells engraft within the epidermis and proliferate in vivo with no evidence of cell fusion. J Pathol (2005) 1.16

Antenatally detected urinary tract abnormalities: more detection but less action. Pediatr Nephrol (2008) 1.15

Rab11 and its effector Rab coupling protein contribute to the trafficking of beta 1 integrins during axon growth in adult dorsal root ganglion neurons and PC12 cells. J Neurosci (2010) 1.15

Alphav beta3 integrin limits the contribution of neuropilin-1 to vascular endothelial growth factor-induced angiogenesis. J Biol Chem (2009) 1.15

ERK1 associates with alpha(v)beta 3 integrin and regulates cell spreading on vitronectin. J Biol Chem (2002) 1.14

Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans. Br J Pharmacol (2013) 1.14

TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer. PLoS One (2013) 1.13

RCP-driven α5β1 recycling suppresses Rac and promotes RhoA activity via the RacGAP1-IQGAP1 complex. J Cell Biol (2013) 1.13

Problems and pitfalls of transition from paediatric to adult renal care. Pediatr Nephrol (2004) 1.13

Rab5c promotes AMAP1-PRKD2 complex formation to enhance β1 integrin recycling in EGF-induced cancer invasion. J Cell Biol (2012) 1.12

Karyomegalic-like nephropathy, Ewing's sarcoma and ifosfamide therapy. Pediatr Nephrol (2011) 1.12

Core competencies for clinical ethics committees. Clin Med (2010) 1.11

Class I Rab11-family interacting proteins are binding targets for the Rab14 GTPase. Biol Cell (2009) 1.11

alpha vbeta 6 Integrin promotes the invasion of morphoeic basal cell carcinoma through stromal modulation. Cancer Res (2008) 1.11

Desmosomal proteins, including desmoglein 3, serve as novel negative markers for epidermal stem cell-containing population of keratinocytes. J Cell Sci (2003) 1.09

Interaction of paxillin with poly(A)-binding protein 1 and its role in focal adhesion turnover and cell migration. Mol Cell Biol (2005) 1.08

ARF6 directs axon transport and traffic of integrins and regulates axon growth in adult DRG neurons. J Neurosci (2012) 1.07

Mutant p53 regulates Dicer through p63-dependent and -independent mechanisms to promote an invasive phenotype. J Biol Chem (2013) 1.07

Primary mouse endothelial cell culture for assays of angiogenesis. Methods Mol Med (2006) 1.07

Altered microenvironment promotes progression of preinvasive breast cancer: myoepithelial expression of αvβ6 integrin in DCIS identifies high-risk patients and predicts recurrence. Clin Cancer Res (2013) 1.06

Foot-and-mouth disease virus forms a highly stable, EDTA-resistant complex with its principal receptor, integrin alphavbeta6: implications for infectiousness. J Virol (2007) 1.06

Aquaporin 2 promotes cell migration and epithelial morphogenesis. J Am Soc Nephrol (2012) 1.05

Standards for renal biopsies: comparison of inpatient and day care procedures. Pediatr Nephrol (2002) 1.04

Genomic amplicons target vesicle recycling in breast cancer. J Clin Invest (2009) 1.04

The role of β3-integrins in tumor angiogenesis: context is everything. Curr Opin Cell Biol (2011) 1.04